Probiotic effect in preterm neonates with sepsis - A systematic review protocol

Background: The microbiota in the intestine is made up of trillions of living bacteria that coexist with the host. Administration of antibiotics during neonatal infection causes depletion of gut flora resulting in gut dysbiosis. Over the last few decades, probiotics have been created and promoted as microbiota management agents to enrich gut flora. Probiotics decrease the overgrowth of pathogenic bacteria in the gut of preterm neonates, reducing the frequency of nosocomial infections in the Neonatal Intensive Care Unit (NICUs). Methods: The systematic review will include randomized control trials (RCTs) of premier neonates with sepsis. Studies will be retrieved from global databases like Cochrane CENTRAL, CINAHL Plus via EBSCO host, MEDLINE via PubMed, EMBASE, SCOPUS, Ovid, Web of Science, ProQuest Medical Library, Microsoft academic, and DOAJ by utilizing database-specific keywords. Screening, data extraction, and critical appraisal of included research will be carried out separately by two review writers. Findings will be reported in accordance with the PRISMS-P 2020 guidelines. Conclusions: The findings of this systematic review will help to translate the evidence-based information needed to encourage the implementation of potential research output in the field of neonatal intensive care, guide best clinical practise, assist policy making and implementation to prevent gut dysbiosis in neonates with sepsis by summarising and communicating the evidence on the topic. PROSPERO registration number: This systematic review protocol has been registered in PROSPERO (Prospective Register of Systematic Reviews) on 10 th March 2022. The registration number is CRD42022315980.


Introduction
According to the Global Burden of Disease (GBD), there are 1.3 million yearly incident cases of neonates sepsis and associated infections (about 937 instances per 100,000 live births) and 203,000 sepsis-related neonatal deaths. 1 A preterm infants' immature intestine predisposes it to infection and inflammation, as it has immature immunity, barrier function, and peristalsis resulting in gut dysbiosis. 2Co-morbidities like c-section deliveries, antenatal and post-natal antibiotic exposure, parenteral nutrition and prolonged stays in a neonatal intensive care unit (NICU), lead to a rapid decrease in taxonomic richness and diversity of good commensal gut bacteria contributing to the loss of colonization resistance. 3,4e gut is the centre of microbial activity; it is essential to address neonatal microbiota dysbiosis as many of the events like period of gestation, method of delivery, dietary patterns, weaning and antibiotic administration play an important role in framing gut microbiota and may have an impact on long term health outcomes. 5,6The host and gut microbiota have unique and cryptic interlinkage; the formation of an individual's gut microbiota starts right from birth and is shaped by various factors.Starting from birth, the gut microbiota plays three critical roles: protective, metabolic, and trophic. 5Gut microbiota carries out their effects by modulating immunologic, endocrine, and neurological pathways. 7e gut also serves as a significant source of noninflammatory immune stimulators in healthy people throughout their lives.However, these beneficial health-promoting factors of the gut microbiota are not infallible and can be altered due to dysbiosis or neonatal infection.Numerous studies have shown that antibiotic consumption causes dysbiosis and disturbance of the gut microbiome in infants, children and adults. 8,90][11] Probiotics are by definition: "live microorganisms that, when administered in adequate amounts, confer a health benefit on the host". 12This definition is a consensus statement by the International Scientific Association for Probiotics and Prebiotics and aligns with the definition accepted by the Food and Agriculture Organization of the United Nations and the World Health Organization (FAO/WHO) published in 2001 (FAO/WHO, 2001) 13 and the guidelines to assist with this definition published in 2002 (FAO/ WHO, 2002).Probiotics can enhance your immune system while preventing the growth pathogenic gut bacteria. 14shift in the composite microbiota system has increased disease risk. 6The use of probiotics facilitates the restoration of the gut microbial profile.It may protect high-risk neonates by preventing the movement of microbes and microbial metabolites across the mucosa, elimination of pathogenic organisms, modifying host reactions to microbial supplements and enhancing nutrition by upregulation of immune response. 15,16A relative reduction in the Bifidobacteriaceae counts and an increase in Enterobacteriaceae and Clostridiaceae may be a good criterion to define dysbiosis in the initial months of life. 11,17It can also explain gut colonization between birth, which can serve as the basis for introducing nutritional strategies targeted at the microbiota.These nutritional interventions, based mainly on probiotics, may be used for favourably altering the gut microbiome and preventing neonatal sepsis.Dysbiosis of the gut microbiome invites the expansion of the pathobiont population, leading to sepsis in neonates. 18Probiotic supplementation aims to rebuild the gut bacteria, preventing necrotizing enterocolitis (NEC), infection and other problems.The initial days of life are crucial for an adequate microbiome that facilitates gut maturation and neonatal health.Therefore, strategies focused primarily on establishing microbiota and consuming probiotic supplements that can help balance the gut microbiota composition, improve well-being, and lower disease risk in neonates.Thomas et al. (2023)  19 conducted a Bayesian network meta-analysis suggesting that probiotics may significantly reduce sepsis and mortality rates in VLBW neonates, emphasizing their importance in resource-limited settings.This review included 29 RCTs with 4,906 neonates and 24 probiotics, but only 11 studies had a low risk of bias.Probiotics were compared with placebos, not with each other.The combination of B. longum, B. bifidum, B. infantis, and L. acidophilus may reduce mortality (RR 0.26; 95% CrI 0.07 to 0.72), sepsis (RR 0.47; 95% CrI 0.25 to 0.83), and NEC (RR 0.31; 95% CrI 0.10 to 0.78), though evidence is uncertain.B. lactis alone may also reduce mortality (RR 0.21; 95% CrI 0.05 to 0.66) and NEC (RR 0.09; 95% CrI 0.01 to 0.32), but evidence is low-certainty. 19Kulkarni et al., in their REVISED Amendments from Version 2 This version of the manuscript includes updates and revisions based on detailed feedback to enhance clarity, accuracy, and comprehensiveness.Key changes include incorporating recent systematic reviews by Kulkarni et al. (2022) and Thomas et al.  (2023) in the introduction to provide context and rationale for the research.The definition of probiotics has been updated to include the consensus statement by Hill et al. (2014) and references to the FAO/WHO definitions.The term 'flora' has been replaced with 'microbiota' throughout the manuscript, and up-to-date nomenclature for bacterial phyla and genera has been adopted following Oren & Garrity (2021) and Zheng et al. (2020).These revisions aim to improve the manuscript's overall readability, precision, and adherence to current scientific standards and terminology.
Any further responses from the reviewers can be found at the end of the article systematic review, highlighted both the benefits and potential risks of probiotic use, stressing the need for rigorous trials to confirm safety and efficacy. 20Despite these comprehensive reviews, gaps remain in the evidence regarding the optimal strains, dosages, and treatment durations of probiotics, as well as their long-term effects on neonatal health.This systematic review protocol aims to address these gaps by synthesizing current evidence on the probiotic effect in preterm neonates with sepsis.

Description of the intervention?
Probiotics supplements help revive the disrupted gut microbiota and prevent gut inflammation and other intestinal diseases. 21Probiotics decrease the overgrowth of pathogenic bacteria in the gut of preterm neonates, reducing the frequency of nosocomial infections in the Neonatal Intensive Care Unit (NICU). 22According to systematic evaluations of randomized controlled trials (RCT), probiotics have substantial potential to lower mortality and morbidity in premature neonates.A systematic assessment of RCT narrated the benefits of probiotics in low-and middle-income countries. 11The supplements may restore the composition of the gut microbiome and introduce beneficial functions to gut microbial communities.According to recent randomized controlled research, early probiotic use may have the capacity to alter the gut microbiota during antibiotic treatment recovery. 23obiotics are becoming more well acknowledged as a valuable tool for promoting health and preventing adverse health outcomes in premature neonates. 24,25They may protect high-risk neonates by increasing the barrier for migration of bacteria and their products across the mucosa, by elimination of potential pathogens, by modifying host response to microbial products, and enhancing nutrition by upregulation of the immune response. 26This study aims to evaluate the effect of probiotics on the gut health and growth of preterm infants in neonates with sepsis.We hypothesized that the administration of specific probiotics could improve the gut microbiota of preterm neonates by lowering the risk of morbidity and mortality with sepsis.

How might the intervention work?
Over the last few decades, probiotics have been created and promoted as microbiota management agents to enrich gut microbiota.Early life is a crucial time for the gut of neonates to be gradually colonised with different species of bacteria that collectively promote initial gut maturation.Bacterial diversity in preterm neonates is low and comparatively different from term neonates. 21Probiotic supplements may help to restore the gut microbiome composition and introduce beneficial functions to gut microbial communities, resulting in the improvement or prevention of inflammation of the gut and other phenotypes of systemic or intestinal diseases. 27obiotic supplement in preterm has been proven to decrease pathogen overgrowth and promote the maturation of the intestinal mucosa by facilitating the growth and proliferation of probiotic bacteria in the intestinal tract. 28Antibiotic exposure was observed to significantly alter gut microbiota, with a considerable reduction in Bifidobacterium and Lactobacillus, according to Zhong et al., 2021. 23The administration of probiotics concurrently with antibiotics was more advantageous to the gut microbiota than waiting until after antibiotic therapy to use probiotics, especially in terms of increasing Bifidobacterium abundance. 23Pneumonia and sepsis accounted for 46% of all admission diagnoses and were attributed to 29% of the overall death rate, compared to 26% globally. 29e mode of delivery influences the gut microbial pattern.Several high-quality studies suggest that bacterial diversity differs among babies based on the mode of delivery.Neonates born by vaginal delivery swallow the vaginal bacteria on their way down the birth canal, which results in the primary source for initial seeding of microbiota to the neonatal gut.Over the initial year of life, there is an abundance of Bifidobacterium spp.and a decrease of Enterococcus spp.and Klebsiella spp. 30Microbiota of caesarean section neonates show distinctly different gut microbiota than vaginally delivered infants and are more likely to have skin, breastmilk, oral and environmental bacteria. 31y it is important to do this review Infections spread rapidly in preterm infants, resulting in severe disease and death; therefore, infection prevention directly reduces neonatal morbidity and mortality.In a systematic review conducted by Balasubramanian et al. among preterm infants in India, metanalysis showed a significantly lower risk in blood culture positive Late-Onset Sepsis (LOS) after 48 hours of birth in the probiotic group (p < 0.001). 25A double-blinded, placebo-randomized controlled trial was conducted using Bacillus clausii to prevent LOS in 244 preterm infants.Of that, 120 were extremely preterm neonates, of which 59 received a placebo and 61 received probiotics.On other hand, 124 babies were stratified as preterm, 61 neonates received a placebo and 61 received probiotics.The study concluded that prophylactic administration of B. clausii to preterm neonates did not result in a significant difference in LOS incidence compared with placebo. 32e gut microbiome is a complex and dynamic population of hundreds of bacteria responsible for transporting nutrition, controlling intestinal epithelial maturation, and building an innate immune defence in neonates.An RCT was conducted by Panigrahi et al. to prevent sepsis among rural Indian neonates.Researchers used Limosilactobacillus plantarum plus fructooligosaccharide as a probiotic on 4,556 neonates of birthweight < 2000 grams, gestational age ≥ 35 weeks with no sign of sepsis and morbidity and were recruited and monitored for 60 days; a significant decrease in neonatal sepsis (culture-positive sepsis, culture-negative sepsis) and lower respiratory tract infections were observed.The study's findings suggested that neonatal sepsis in developing countries could be effectively prevented using a symbiotic containing L. plantarum ATCC-202195. 33The findings of this systematic review would definitively answer whether early administration of specific probiotics could improve the gut microbiota of preterm neonates by lowering the risk of infant morbidity and mortality in neonates with sepsis, and assist healthcare providers and policymakers in developing a probiotic supplement guideline for sepsis neonates.

Ethical considerations
As this is a systematic review protocol, ethical approval is not required as we will not be directly involving human participants.

Review questions
How effective is probiotics in lowering the risk of morbidity and mortality among preterm neonates with sepsis?

Specific objectives
To determine the impact of probiotics on lowering the risk of morbidity and mortality among preterm neonates with sepsis.

Design
We will systematically review existing randomized and non-randomized control trial studies and execute a meta-analysis when acceptable data is available.This protocol follows the recommendations of the Preferred Reporting Items for Systematic Review and Meta-Analyses of Protocols (PRISMA-P) 2015. 44The Participants, Interventions, Comparators and Outcomes elements used for the systematic review are listed in Table 1.
Search for other resources Additional references will be found in the reference lists of all primary research and review papers.To get necessary supplementary information, we will reach out to relevant field experts and researchers from the included papers.For data management, records will be exported to EndNote X7.

Selection of studies
Two review authors (FI, SN) shall execute independent searches of the study titles and abstracts of the indicated study sources.We shall exclude the articles which do not meet the inclusion criteria.If there is a disagreement among those reviewers, it will be resolved through conversation, and the complete text will be examined.Two reviewers will independently assess the included abstracts as "include" or "exclude" after obtaining the whole manuscript.If required, we will work with a supervisory review author (LEL) to address any disagreements.We will keep track of why the articles were refused.We will look for and eliminate duplicates and compile numerous reports from the same research.

Data extraction and management
Data will be extracted by examining general features such as gestational age, research participants, setting, identifiers, type of pathogen isolated, LOS, early-onset sepsis (EOS), type of probiotic, study selection criteria, and results.
To organize the list of intervention parameters to assist intervention replication and research comparability, we will use the TIDier checklist (Template for Intervention Description and Replication). 34Additionally, we will extract data of specific characteristics such as type of probiotic used, dosage, antibiotic exposure, gestational age and type of delivery.
Two review authors will independently use the data extraction templates to abstract the data from included articles in the review.The included studies will have the following data collected: research title and authors, sample size, study setting, intervention features, assessment procedures, outcomes, findings, conclusions, and year of publication.If there is a disagreement, we will discuss it until we reach an agreement, or we will handle it with the assistance of a third reviewer (MKR).

Assessment of quality of the studies
We will assess the quality of included randomized controlled trials using the Revised Cochrane Risk of Bias Tool (RoB 2.0).The RoB 2.0 tool considers the following factors: a) The randomization method, b) deviation from the planned intervention, c) outcome measurement, d) missing outcomes, and e) selective reporting.Two authors will independently evaluate each paper.RCT risk will be assessed and classified into three categories: low risk, high risk, and some concerns. 35To assess the quality of the included non-randomized controlled trials, we will use the Joanna Briggs Institute (JBI) Critical Appraisal Checklist.If there is any disagreement, we will solve it by contacting a methodology expert (BSN).

Dealing with missing data
We will contact the primary authors whenever possible to obtain the missing data.The most important empirical data, including screening, randomization, intention-to-treat, as-treated, and per-protocol groups, will be investigated thoroughly.The article will be excluded from the review if the authors do not respond within two weeks after communicating through email.If this is not possible, we will consider the missing data a major bias, and the article will be removed from consideration.

Data synthesis
Two independent reviewers (FI and SN) will extract the data from each study and enter it into a Microsoft Excel file Version 16.61.Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) standards will be used to provide evidence regarding the effect of probiotics on the gut health of preterm neonates with sepsis (Extended data 43 ). 36f there is sufficient homogeneity in study design and study subjects among the selected studies, meta-analyses will be conducted. 37As a result, continuous and dichotomous outcomes will be integrated for meta-analysis purposes.Statistical analyses will be conducted with the help of the Cochrane Review Manager (RevMan 5).

Sensitivity analysis
Sensitivity analysis will be performed to investigate the robustness of the results by examining the effects of including and excluding studies with a high risk of bias and studies with missing data.The results' robustness will be evaluated using a variety of impact size measures, such as risk ratio and odds ratio, and various statistical models, such as fixed effects and random-effects models.

Discussion
The microbiota in the intestine is made up of trillions of living bacteria that coexist with the host.Depleting gut microbiota in neonates, especially in vulnerable preterm neonates, may elevate the risk of neonatal infections resulting in administration of antibiotics. 38Antibiotics are pharmacological agents that destroy the bacteria cells, 39 but not viruses that are also possible gut pathogens.Probiotic supplementation has become increasingly popular in the fight against gut microbiota depletion. 17,23,24e impact of probiotics on neonatal health has been extensively studied, and several randomized controlled trials have demonstrated significant benefits.A randomized control trial was conducted by Zhong et al. to assess the impact of probiotic supplements on 90 neonates with gestational age ≥ 37 weeks.They concluded that antibiotics cause a decrease in the microbial richness and variety of the gut microbiota in neonates and the attenuation of several bacteria, especially Bifidobacterium and Lactobacillus. 23A significant reduction in newborn sepsis has been reported in randomized controlled trials (RCTs) of various probiotic strains and combinations given to preterm infants of different gestational ages and birth weights.Panigrahi et al., in their randomized control trial, examined the effect of probiotics in neonatal sepsis and showed a significant reduction in neonatal sepsis cases when supplemented with Limosilactobacillus plantarum. 40

Strengths and limitations of the study
This systematic review will include randomized controlled trials and all types of non-randomized control trials.Metaanalysis will be carried out with the results of RCTs, and narrative description will be used to analyse non-randomized control trials regarding the effect of probiotics among preterm neonates with sepsis.This review includes only the use of probiotics in preterm infants, excluding the studies that assessed the effect of prebiotics and synbiotics among preterm neonates.Only studies published in English will be included; thus, eligible studies published in other languages will be excluded.

Yao Wang
The Chinese University of Hong Kong, Hong Kong, Hong Kong Sepsis is a severe condition that threatens fetal health.Applying probiotics is a feasible and potential approach to prevent this disease.Therefore, this study is meaningful with significant clinical implications.The methods and study design are clear and reasonable.Importantly, the authors will extract specific data such as the type of probiotic used, dosage, antibiotic exposure, gestational age, and type of delivery.
One suggestion is that the details of probiotics should be clearly documented at the species or strain level if the data allows.Moreover, the prescribed model, including the starting point of administration during pregnancy and the duration of probiotic use, should also be included.All these contents are crucial to help clinicians to understand and make decisions.

Sabina Fijan
Faculty of Health Sciences, University of Maribor, Maribor, Slovenia

Probiotic effect in preterm neonates with sepsis -A systematic review protocol: Review report
This manuscript, submitted to the journal f1000Research, is a crucial topic and describes the protocol to conduct a systematic review of the probiotic effect in preterm neonates with sepsis.

General comments
Recent systematic reviews on this subject have been published and should be referenced with the rationale for conducting similar research (Kulkarni et  The human microbiota comprises of bacteria, archaea, viruses, fungi and other eukaryotes that coexist in and on various sites of the human body (Hou et al., 2022), while the microbiome is the collection of all genetic information of this microbiota (Grice & Segre, 2012; Ogunrinola et al.,  2020).The term 'flora' is outdated and should be replaced by the taxonomically correct term 'microbiota.
When comparing the modulation of gut microbiota, the abundance or ratio of certain phyla is usually compared (Walsh et al., 2014).However, it is necessary to use up-to-date nomenclature (Oren & Garrity, 2021).Firmicutes are now Bacillota, Proteobacteria are now Pseudomonadota, Actinobacteria are now Actinomycetota, Bacteroidetes are now Bacteroidota etc.
Up-to-date terminology should be used for lactobacilli (Zheng et al., 2020) Another important factor is the meaning of probiotics.Only certain strains are probiotic microbes.
The strains that are labeled as a probiotic must have at least on quality double blind randomised controlled clinical study that exhibits a statistically significant difference in the group that was supplemented with probiotics compared to the placebo group (Binda et al., 2020).And in many instances the health benefits are strain-specific, therefore strain information must be included.For example, Lacticaseibacillus rhamnosus GG (previously known as Lactobacillus rhamnosus GG) is a well-known probiotic with several proven health benefits (McFarland et al., 2021; Tan et al., 2021).However, this does not mean that all strains of the species Lacticaseibacillus rhamnosus are probiotics, let alone all lactobacilli.The same applies for Limosilactobacillus reuteri strains, Lactiplantibacillus strains, and many others.

Minor corrections
Introduction, paragraph 3: please correct the sentence to 'probiotics can enhance your immune system while preventing the growth pathogenic gut bacteria'.Comment #6:Another important factor is the meaning of probiotics.Only certain strains are probiotic microbes.The strains that are labeled as a probiotic must have at least on quality double blind randomised controlled clinical study that exhibits a statistically significant difference in the group that was supplemented with probiotics compared to the placebo group (Binda et al., 2020).And in many instances the health benefits are strainspecific, therefore strain information must be included.For example, Lacticaseibacillus rhamnosus GG (previously known as Lactobacillus rhamnosus GG) is a well-known probiotic with several proven health benefits (McFarland et al., 2021; Tan et al., 2021).However, this does not mean that all strains of the species Lacticaseibacillus rhamnosus are probiotics, let alone all lactobacilli.The same applies for Limosilactobacillus reuteri strains, Lactiplantibacillus strains, and many others.

Authors Reply:
Modified accordingly in manuscript Minor corrections Comment #7:Introduction, paragraph 3: please correct the sentence to 'probiotics can enhance your immune system while preventing the growth pathogenic gut bacteria'.

Authors Reply:
The sentence has been corrected to "Probiotics can enhance your immune system while preventing the growth of pathogenic gut bacteria." Comment #8: Assessment of quality of the studies: please add the foreseen Joanna Briggs Institute Critical appraisal tool checklist for randomised controlled trials.

Introduction
First, majority of the systematic reviews published do not have subsections under this portion.
Having sub sections probably is beneficial when the author writes the Introduction.However, reading is made smooth if there were no sub sections.Second, the specific objective which was supposed to be in this section was found in the Methods section.Last, the stated objective of the study does not jive with the stated hypothesis.The premise "growth of preterm infants" was included in the objective but absent in the hypothesis.
that will be followed during the review process.
The use of future tense in the protocol is intentional and necessary because, protocols are typically written before starting the search and data extraction process.At this stage, the review team has not yet gathered and analyzed the data, so it would be premature to present any results.Instead, the protocol serves as a blueprint for the systematic review, detailing the research questions, eligibility criteria, search data extraction methods, and analysis plan.
Rest assured that once the systematic review is completed, we will publish the results in a separate paper or report, where we will present and discuss our findings based on the data collected and analyzed during the review process.This follow-up publication will provide a comprehensive overview of the results and their implications.
We hope this clarifies the purpose and scope of our systematic review protocol.We value your input and appreciate your understanding of the process.If you have any further questions or suggestions, please feel free to share them.

Competing Interests: No competing interests
The benefits of publishing with F1000Research: Your article is published within days, with no editorial bias • You can publish traditional articles, null/negative results, case reports, data notes and more • The peer review process is transparent and collaborative • Your article is indexed in PubMed after passing peer review • Dedicated customer support at every stage • For pre-submission enquiries, contact research@f1000.com
Costeloe et al. evaluated the effect of Bifidobacterium breve strain BBG-001 on the development of sepsis or NEC in very low birth weight neonates.At two weeks postnatal age, he observed B. breve colonisation in 1186 (94%) survivors.There were 85% in the probiotic group and 37% in the placebo group.41

Open Peer Review Current Peer Review Status: Version 3
Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).Bowler U, Brocklehurst P, et al.: A randomised controlled trial of the probiotic Bifidobacterium breve BBG-001 in preterm babies to prevent sepsis, necrotising enterocolitis and death: the Probiotics in Preterm infantS (PiPS) trial.Health Technol.Assess.(Winch.Eng.).2016Aug; 20(66): 1-194.This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Is the rationale for, and objectives of, the study clearly described? Yes Is the study design appropriate for the research question? Yes Are sufficient details of the methods provided to allow replication by others? Yes Are the datasets clearly presented in a useable and accessible format? Yes Competing Interests:
An example study is Bekalu et al., AJOG FMF 2023.10.1016/j.ajogmf.2023.101148.I am overall content if the authors could further improve above comments.No competing interests were disclosed.

have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Version 2
Reviewer Report 13 June 2024 https://doi.org/10.5256/f1000research.157165.r278782© 2024 Fijan S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

live microorganisms that, when administered in adequate amounts, confer a health benefit on the host
al., 2022;Thomas et al., 2023)."(Hilletal., 2014).This definition is published as a consensus statement by the International Scientific Association for Probiotics and Prebiotics and should be referenced when citing the correct definition.This definition is in line with the definition accepted by the Food and Agriculture Organization of the United Nations and the World Health Organisation (FAO/WHO) published in 2001 (FAO/WHO, 2001) and the guidelines to assist with this definition published in 2002 (FAO/WHO, 2002).
use accurate phrases.antibioticsarepharmacologicalagents that destroy the bacteria cells(Patel P et al., 2023), but not viruses that are also possible gut pathogens.connectivesentencesshouldbeincluded,notjustthepresentation of results of randomised controlled trials.When referring to the conductors of clinical trials please use the term 'they'.When comparing the modulation of gut microbiota, the abundance or ratio of certain phyla is usually compared(Walsh et al., 2014).However, it is necessary to use up-todate nomenclature(Oren & Garrity, 2021).Firmicutes are now Bacillota, Proteobacteria are now Pseudomonadota, Actinobacteria are now Actinomycetota, Bacteroidetes are now Bacteroidota etc. Up-to-date terminology should be used for lactobacilli(Zheng et al., 2020).This genus Lactobacillus has been divided and now consists of 25 genera.It is necessary to include the new nomenclature of many species that contain probiotic strains, for example: Limosilactobacillus reuteri (previously Lactobacillus reuteri), Limosilactobacillus reuteri (previously Lactobacillus reuteri), Lactiplantibacillus plantarum (previously Lactobacillus plantarum), Levilactobacillus brevis (previously Lactobacillus brevis), Lacticaseibacillus rhamnosus (previously Lactobacillus rhamnosus), Ligilactobacillus salivarius (previously Lactobacillus salivarius).The new nomenclature can be found at the website: http://lactotax.embl.de/wuyts/lactotax/.Other genera that also include probiotic strains such as Bacillus, Clostridium, Propionibacterium have also undergone taxonomic reclassification(Gupta et al., 2020; Lawson et al., 2016; Scholz & Kilian, 2016).
○Assessment of quality of the studies: please add the foreseen Joanna Briggs Institute Critical appraisal tool checklist for randomised controlled trials.○ Discussion: paragraph 1: please ○ Discussion: paragraph 1: some ○ Comment #4: